about
Immune Checkpoint in Glioblastoma: Promising and ChallengingA nested case-control study of 277 prediagnostic serum cytokines and glioma.Recent advances and future of immunotherapy for glioblastoma.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Engineering challenges for brain tumor immunotherapy.Cytokines in immunogenic cell death: Applications for cancer immunotherapy.HSP70-based anti-cancer immunotherapy.Gene Delivery in Neuro-Oncology.Biomarkers and therapeutic advances in glioblastoma multiforme.Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.C1-inactivator is upregulated in glioblastoma.PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma PatientsGuidelines for the use of flow cytometry and cell sorting in immunological studies.Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model.Vaccination in the immunotherapy of glioblastoma.Current and emerging EGFR therapies for glioblastoma.PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Current state and future prospects of immunotherapy for glioma.Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1.Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.Impact of atopy on risk of glioma: a Mendelian randomisation study.New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.A Non-randomized Controlled Trial of EMDR on Affective Symptoms in Patients With Glioblastoma Multiforme.Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model.Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain gliomaCurrent status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas
P2860
Q33650058-35205877-8543-4D95-9341-48AF2D404B31Q33778545-2D581AA5-B2FE-48A4-AC35-A0332816CA44Q37239071-E576A38F-8D1F-4A25-A76E-D6E7AAEBCCE9Q38811369-F0D41C1D-CA52-4A4F-A9D4-E02C8E1CB998Q38940348-6B08E571-E677-4CE1-AB95-CDF86773BC89Q38987239-023BA640-FED7-45C8-B000-FAE9BE6A61FAQ39381281-6F38A50B-0C88-4950-9F09-D8732FBBA26AQ39397491-40B5FC8A-9795-44CC-8D33-E2C1495659A0Q39688737-431997E2-5FA1-404B-836C-852D981D5CF4Q40060078-06ACC2ED-055C-4DCD-B7A7-CAB2BD6AB818Q40070524-3BFDE71E-60D0-4CF4-8DB5-B6962CEC173BQ41576716-D77835C4-C806-4E14-B376-C8AA2CDF4CA7Q41577019-DCF7EB9F-EAF1-45E8-B435-2BD58B5440C3Q41903951-B35147A1-42B6-4C43-8E38-2CD0A3752AF0Q41918189-47C6D6B1-FDA4-45DF-A516-31B0F2F74FB5Q47100447-B6EC3259-3377-4171-8756-08D85CC2C8D7Q47148959-6EBD380B-6067-47FA-98D8-733157364A33Q47583155-84446AE9-E32C-42F7-9373-170C5AFA79DAQ47878958-37365615-740C-4CFB-8DDC-FB7DEF57D724Q49359656-24DF2AD3-307E-4249-ADB5-8D0CED326D44Q50109459-59CC6C8E-CCFD-41BC-9A1D-681AB7855665Q51746207-FB5D71AC-7FC6-4F00-B22A-9CF3D2F27B4EQ52366335-402FA17D-65E2-47C8-9C0B-7D507331760EQ52590668-A2DCB1C7-4A7A-4996-87DE-3AAFBA0D30A1Q52655627-19AD5430-5E54-4D15-8046-0DE9242DF1BBQ52691329-B9AAF624-098B-482E-BF5E-FF189F3FDF8BQ52780147-E7E2072D-FB63-48BC-81D5-D87D087C54E2Q54980235-85FA92D3-5E97-4E88-AD9D-5909D2F49A1CQ55224144-F0640F04-C4D0-4653-BEE7-49B16348DAC4Q55278851-13DD5B80-B02C-40B8-A000-4D5380A01F90Q55309037-AB410175-856D-4A0D-BECB-462CFA156414Q55342124-25068A86-A177-4E4C-9EFD-4DBC5887BBE1Q55457493-8C3C58A0-3CEC-427B-81CA-7E17C88F5CADQ55663256-04D77007-086E-44F4-9099-C8843A87716FQ58693796-7E289B9F-D881-4E63-94B3-7EC29995DA1BQ58707289-01DDAAD3-7CDB-4D71-8E45-CE2656AC8244
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Immune Evasion Strategies of Glioblastoma
@ast
Immune Evasion Strategies of Glioblastoma
@en
Immune Evasion Strategies of Glioblastoma
@nl
type
label
Immune Evasion Strategies of Glioblastoma
@ast
Immune Evasion Strategies of Glioblastoma
@en
Immune Evasion Strategies of Glioblastoma
@nl
prefLabel
Immune Evasion Strategies of Glioblastoma
@ast
Immune Evasion Strategies of Glioblastoma
@en
Immune Evasion Strategies of Glioblastoma
@nl
P2093
P2860
P3181
P356
P1433
P1476
Immune Evasion Strategies of Glioblastoma
@en
P2093
Benjamin E Jin
Karen E Lee
Parvir S Aujla
Seyed-Mostafa Razavi
Sharareh Gholamin
P2860
P3181
P356
10.3389/FSURG.2016.00011
P407
P577
2016-01-01T00:00:00Z